COMMUNIQUÉS West-GlobeNewswire

Cannabix Technologies Launches New Marijuana Breath Test Product Videos as U.S. Cannabis Reclassification Underscores the Urgent Need for Innovative Public Safety Solutions
19/12/2025
VANCOUVER, British Columbia, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is [...]
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
19/12/2025
DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure [...]
OncoInv and MaxBloch Partner to Expand Early Cancer Detection Across Central America
19/12/2025
OncoInv has signed a distribution partnership with MaxBloch Clinical Laboratories to introduce the OncoSeek® multi-cancer early detection blood test in El Salvador, expanding access to affordable early cancer detection [...]
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
19/12/2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Tevogen CEO Donates Personal Shares to Support Local Fire Department
19/12/2025
WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal [...]
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
19/12/2025
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for [...]
Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
19/12/2025
Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE [...]
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
19/12/2025
MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, [...]
Glass House Brands Applauds Cannabis Reform Action
19/12/2025
LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
19/12/2025
Total national coverage footprint for PENFS increases to roughly 100 million covered lives CARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical [...]
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
19/12/2025
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by [...]
Cue Biopharma Announces Pricing of $10 Million Public Offering
19/12/2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
19/12/2025
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
19/12/2025
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi [...]
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
19/12/2025
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
19/12/2025
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing [...]
Sienna Completes Acquisition in the Greater Toronto Area
19/12/2025
This news release constitutes a “designated news release” for the purposes of Sienna’s amended and restated prospectus supplement dated November 14, 2025 to its short form base shelf prospectus dated November 29, 2024. [...]
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals
19/12/2025
ATHENS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals, Inc.’s (OTC: NDTP) wholly-owned subsidiary Good Salt Life, Inc. , a pioneer in innovative surface treatment and biosecurity solutions, announces a [...]
Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
19/12/2025
HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extended The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental [...]

Pages